Catalysis of Thrombin Inhibition Provides an Index for Estimating the Antithrombotic Potential of Glycosaminoglycans in Rabbits

Summary

Previous studies have demonstrated that standard anticoagulant tests are poor indices of the antithrombotic potential of glycosaminoglycans which are weak catalysts of the thrombinantithrombin III reaction. In this study we investigated whether the catalysis of thrombin inhibition by plasma could serve as a reliable index for assessing the antithrombotic effectiveness of glycosaminoglycans. Equal volumes of ¹²⁵I-thrombin and control or test plasma were incubated for up to 10 min at 37° C. Inactivation of thrombin was then determined after 7.9% SDS-polyacrylamide gel electrophoresis and subsequent autoradiography. Increasing concentrations of heparin (>0.066 μg/mL or 0.01 USP units/mL) and dermatan sulfate (>0.1 μg/mL) could be readily demonstrated in undiluted plasma by enhanced formation of complexes of thrombin with antithrombin III and heparin cofactor II respectively. However, the detection of any catalytic effect of the two glycosaminoglycans decreased significantly with increasing plasma dilutions. When ex vivo plasmas obtained from rabbits that had been injected with the minimum dose of any one of seven glycosaminoglycans required to achieve their optimal antithrombotic effect were assessed for their ability to catalyse thrombin inhibition, there was approximately a 2-fold increase in the amount of thrombin inactivated 30 s after the thrombin had been added to the plasma. The enhanced inhibition of thrombin was achieved by catalysis of antithrombin III and/or heparin cofactor II activities. These results suggest that measurement of the catalysis of thrombin inactivation in undiluted plasma is a sensitive and reliable index for estimating the antithrombotic potential of glycosaminoglycans in rabbits.

Keywords

Antithrombotic - Heparin cofactor II - Antithrombin III - Thrombin inhibition

• References

• 1 Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition to the antithrombotic effect of heparin. Blood 1985; 65: 198-201
• 2 Ofosu FA, Blajchman MA, Modi GJ, Smith LM, Buchanan MR, Hirsh J. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulfate, low molecular weight heparin and pentosan polysulfate. Brit J Haematol 1985; 60: 695-704
• 3 Holmer E, Mattson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
• 4 Barrowcliffe TW, Merton RE, Havercroft SJ, Thunberg L, Lindahl U, Thomas DR. Low-affinity heparin potentiates the action of high affinity heparin oligosaccharides. Thromb Res 1984; 34: 125-134
• 5 Ofosu FA, Cerskus AL, Hish J, Smith LM, Modi GJ, Blajchman MA. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids and tissue factor. Brit J Hematol 1984; 57: 229-238
• 6 Boneu B, Buchanan MR, Cade JF, Van Ryn J, Fernandez FA, Ofosu FA, Hirsh J. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo . Thromb Res 1985; 40: 81-89
• 7 Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J. A comparison of antithrombotic and hemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation. Thromb Res 1984; 35: 613-625
• 8 Carter CJ, Kelton J, Hirsh J, Gent M. The relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin. Thromb Res 1982; 21: 169-174
• 9 Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The hemorrhagic and antithrombotic effects of dermatan sulfate. Brit J Haem 1986; 64: 309-317
• 10 Ockelford PA, Carter CJ, Mitchell L, Hirsh J. Discordance between anti-factor Xa activity and the antithrombin activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982; 23: 331-335
• 11 Thomas DP, Johnson EA, Barrowcliffe TW. The antithrombotic action of heparan sulfate. In: Vascular Occlusion: Epidemiological, Pathophysiological & Therapeutic Aspects. Tesi M, Dormandy JA. (eds.). Academic Press; London: 1981. pp 377-382
• 12 Ofosu FA, Modi GJ, Smith LM, Cerskus AL, Hirsh J, Blajchman MA. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984; 64: 742-747
• 13 Fenton JW, Fasco MJ, Stackrow AB, Aronson PL, Young AM, Finalyson JS. Human thrombins. Production, evaluation and properties of a-thrombin. J Biol Chem 1977; 252: 3587-3589
• 14 Tollefsen DM, Petska CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
• 15 Tollefsen DM, Majerus DM, Blank MK. Heparin cofactor II. Purification and properties of a heparin dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169
• 16 Steiner JP, Battacharya P, Strickland DK. Thrombin-induced conformational changes of human α₂-macroglobulin: evidence for two functional domains. Biochemistry 1985; 24: 2993-3001
• 17 Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U. Effect of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thrombos Haemostas 1982; 24: 2993-3001
• 18 Carlson TH, Attencio AC. Isolation and partial characterization of two distinct types of antithrombin III from rabbits. Thrombos Res 1982; 27: 23-34
• 19 Carlson TH, Attencio AC, Simon TL. Compartison of the behaviour in vivo of two molecular forms of antithrombin III. Biochem J 1985; 225: 557-564
• 20 Lollar P, Owen WG. Clearance of thrombin from circulation by high affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III. J Clin Invest 1980; 66: 1222-1230
• 21 Marcum JA, Rosenberg RD. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 1984; 23: 1730-1737